Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

Phase 2 Active not recruiting 219 enrolled UNICANCER

RandomizedParallel-groupOpen-labelTreatment

Summary

National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis. Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.

Timeline

Start: 2016-12
Primary completion: 2025-12
Completion: 2026-01

Publications

Pisareva E, Mihalovicova L, Pastor B, Kudriavtsev A, Mirandola A, Mazard T, Badiou S, Maus U, Ostermann L, Weinmann-Menke J, Neuberger EWI, Simon P, Thierry AR. Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA. Genome Med. 2022 Nov 28;14(1):135. doi: 10.1186/s13073-022-01125-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	150 mg/m2	Intravenous
Comparator	Leucovorin	Small molecule	400 mg/m2	Intravenous
Comparator	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Comparator	Panitumumab	Monoclonal antibody	—	—
Comparator	Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil	Unknown	2400 mg/m2	—

Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

Summary

Timeline

Publications

Drugs

Indications